Purdue Institute for Drug Discovery

Pipeline Entities Overview

FDA Approved:

Phase 3:

Phase 2:

Phase 1:

LMP400 (indotecan)

LMP776 (indimitecan)

Pre-clinical:

SHP2 inhibitors - oncology

DESI diagnostic

Glucagon derivatives

TC-PTP degraders

In Vivo Efficacy:

CDK7 inhibitors

CDK12/13 inhibitors

GRK2 inhibitors

MPTPB inhibitors

Niclosamide-OHPP

PTPN22 inhibitors

SHP2 inhibitors - immunology

SHP2 inhibitors

PLS Lung Surfactant

177Lu-Folate-DOTA

STING antagonist

CAI0031

NNMT inhibitors

NTMT1 inhibitor

Pipeline Entities Overview